# Solara Active Pharma Sciences share price today (Solara Active Pharma Sciences Ltd, NSE: SOLARA)

> Solara Active Pharma Sciences share price today: ₹629.75 at the NSE close on 3 November 2026, up 5.0% in a year. Solara Active Pharma Sciences (NSE: SOLARA) is worth ₹3,054 crore, trades at a P/E of 64.6 and has closed between ₹441.25 and ₹749.15 over the past 52 weeks. > Solara Active Pharma Sciences Ltd's share price has risen faster than its earnings: +5.0% in a year, against −1,466.7% for earnings per share. SOLARA · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹629.75 (+5.0% in a year)
- P/E: 64.6× (higher than 65% of the last 8.1 years)
- Revenue (Sep 2026): ₹417 Cr (+32.8% on a year ago)
- Profit (Sep 2026): ₹28.0 Cr
- Operating margin: 18.0% (+7.0 points on a year ago)
- ROCE: 5%, FY26
- ROIC: 6.8%, against a 12.0% cost of capital: −5.2 points
- Profit that came in as cash: 181%, last 3 years

The main question: the share price moved +5.0% in a year while yearly earnings per share moved −1,466.7%. The difference came from the market paying a higher multiple. ## What is the Solara Active Pharma Sciences share price today? Solara Active Pharma Sciences Ltd's share price was ₹629.75 at the close on 3 November 2026. It has been rising for 19 weeks. That is 6.6% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 12 weeks in a row. In the last 52 weeks it traded between ₹441 and ₹749, and at that close it sat 61% of the way up from that low. Over the last 8.3 years the share price moved +201% while the NIFTY 500 moved +138%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Solara Active Pharma Sciences this quarter? Three changes stood out: highest quarterly profit in 16 quarters, operating margin up 7 points on a year earlier and revenue up on a year earlier for 4 quarters in a row. 1. Highest quarterly profit in 16 quarters Profit of ₹28 crore in the September 2026 quarter is the highest of the last 16 quarters. Why: Profit rose because the base business sold more. Next results: check whether profit stays at or above this quarter's level for another two quarters, the CEO's own test for a turnaround. From the earnings call on 16 Oct 2026. 2. Operating margin up 7 points on a year earlier 18% in the September 2026 quarter, from 11%. Why: Operating margin rose because operating costs stayed broadly flat, so more of the extra gross profit reached operating profit. Next results: check whether customer price increases cover the higher raw material costs from West Asia, so the base gross margin starts to recover. From the earnings call on 16 Oct 2026. 3. Revenue up on a year earlier for 4 quarters in a row In the September 2026 quarter revenue was ₹417 crore, +32.8% on a year earlier. Why: Revenue rose because demand for the base business's active ingredients was good, with more customers and products made. Next results: check whether the three remaining drug filings are submitted by the end of the fiscal year. From the earnings call on 16 Oct 2026. ## What are Solara Active Pharma Sciences' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Solara Active Pharma Sciences reported revenue of ₹417 crore, up 32.8% from ₹314 crore a year earlier, and a profit of ₹28.0 crore, against a loss of ₹10.0 crore a year earlier. ### Solara Active Pharma Sciences results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹417 crore | ₹314 crore | +32.8% |
| Profit | ₹28.0 crore | loss of ₹10.0 crore | n/a |
| Earnings per share | ₹5.86 | ₹−2.79 | n/a |
| Operating margin | 18.0% | 11.0% | +7.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Solara Active Pharma Sciences' management discussed these results on a call held on 16 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Solara Active Pharma Sciences share price history? Solara Active Pharma Sciences closed at ₹629.75 on 3 November 2026, up 5.0% from ₹599.80 a year earlier (31 October 2025) and down 45.4% over five years. Its highest weekly close since June 2018 was ₹1,637.51 on 6 August 2021. ### Solara Active Pharma Sciences share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹611.55 | +3.0% |
| 1 month ago · 1 Oct 2026 | ₹714.85 | −11.9% |
| 6 months ago · 30 Apr 2026 | ₹495.80 | +27.0% |
| 1 year ago · 31 Oct 2025 | ₹599.80 | +5.0% |
| 3 years ago · 3 Nov 2023 | ₹314.83 | +100.0% |
| 5 years ago · 4 Nov 2021 | ₹1,154.37 | −45.4% |
| Earliest weekly close in our records · 29 Jun 2018 | ₹209.41 | +200.7% |
| Highest weekly close since June 2018 · 6 Aug 2021 | ₹1,637.51 | −61.5% |
| Lowest weekly close since June 2018 · 13 Jul 2018 | ₹138.46 | +354.8% |
| 52-week high (weekly close) · 11 Sep 2026 | ₹749.15 | −15.9% |
| 52-week low (weekly close) · 13 Mar 2026 | ₹441.25 | +42.7% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (443 weekly closes from 29 June 2018 to 3 November 2026.)

## What is the latest news on Solara Active Pharma Sciences? 3 Nov 2026: Solara Active Pharma Sciences closed at ₹629.75, up 3.0% on the week and down 11.9% on the month. 16 Oct 2026: Solara Active Pharma Sciences held its results call for July to September 2026. Management guided: FY27 goal of five DMF submissions, with two completed and three more hoped for by year-end. ### Earlier

- Results for July to September 2026: Revenue up 32.8% on a year earlier. ## What dividend does Solara Active Pharma Sciences pay? Solara Active Pharma Sciences paid no dividend in the 12 months to 4 November 2026. The last was a dividend of ₹3 a share, ex-date 18 August 2021. ### Solara Active Pharma Sciences dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 18 Aug 2021 | ₹3 | Dividend | 20 Aug 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 1 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Solara Active Pharma Sciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 9 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Solara Active Pharma Sciences management say on the latest results call? On the call for July to September 2026, held on 16 October 2026, Solara Active Pharma Sciences' management guided: FY27 goal of five DMF submissions, with two completed and three more hoped for by year-end. > “I would say we have turned around if we can deliver another 2 quarters in line with the current quarter or better than the current quarter. That would qualify as a turnaround for me.”
> Sandeep, on the call for July to September 2026

### What management guided

- Strategic review outcome and next steps within 12 weeks. - Base-business gross margin of 52-55% viewed as sustainable over the medium to long term. - West Asia-driven base gross-margin pressure likely to persist for at least 1-2 more quarters. - Net debt/operating profit expected to remain in a similar range over the medium term. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/34109/Conference Call/CC-Oct26.pdf). (From the call for July to September 2026, 16 October 2026.)

## What to watch in Solara Active Pharma Sciences' next results? When Solara Active Pharma Sciences reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Ibuprofen, Vizag and CRAMS strategy outcome - check for a named operating path, customer process or multiproduct use. - What to check (from the call)
- Ibuprofen, Vizag and CRAMS strategy outcome - check for a named operating path, customer process or multiproduct use. - Base gross-margin recovery - check whether pass-through offsets West Asia-linked input inflation. - DMF submissions - check whether the remaining planned submissions arrive by fiscal year-end. - Receivables conversion - check whether container delays ease and billing-to-shipment time normalizes without changed payment terms. ## Which stock lists is Solara Active Pharma Sciences on? Solara Active Pharma Sciences is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 3096.9340815681317](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 3096.9340815681317](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Solara Active Pharma Sciences profitable? Solara Active Pharma Sciences Ltd earned ₹28.0 Cr of net profit in the Sep 2026 quarter. The full FY26 year was a loss of ₹7.0 Cr. That is 6.7% of the quarter's revenue. The same quarter a year earlier lost ₹10.0 Cr. 6 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was −₹7.0 Cr (−800.0% on the year before). ## How much revenue does Solara Active Pharma Sciences make, and is it growing? Solara Active Pharma Sciences Ltd reported ₹417 Cr of revenue in the Sep 2026 quarter, +32.8% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 8 years it has grown 12.8% a year on average. The last full year, FY26, came in at ₹1,369 Cr. The last four reported quarters add to ₹1,535 Cr. FY26 revenue was ₹1,369 Cr, +6.6% on the year before. Recent pace: the last four quarters grew +27.6% on average, against 12.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +27.3%, against +12.1% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Solara Active Pharma Sciences keep? Solara Active Pharma Sciences Ltd's operating margin was 18.0% in the Sep 2026 quarter, 7.0 percentage points higher than the same quarter a year ago. Across 9 years it has been between −7.0% and 24.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +7.3 percentage points on the year while gross margin changed −2.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Solara Active Pharma Sciences' profit turning into cash? Over the last 3 years, 181% of Solara Active Pharma Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹153 Cr of operating cash against −₹7.0 Cr of profit. After ₹70.0 Cr of spending on assets, ₹83.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 181% of profit came in as cash: the cash cycle got 38 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Solara Active Pharma Sciences' cash go? Solara Active Pharma Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 140 days in FY26, up from 102 days in FY21. It spent ₹143 Cr on assets over the last 3 years. Customers take 117 days to pay, and stock sits for 170 days on average. At FY26 sales of ₹1,369 Cr, each day of that cycle ties up about ₹3.8 Cr, so roughly ₹525 Cr is tied up in the business at any time. FY26: customers took 117 days to pay and stock sat for 170 days, about 5.6 months of sales sitting as stock, for a full cycle of 140 days, longer than FY21's 102. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 170 days. Customers pay about 117 days after that. Suppliers are paid at 146 days. Together that makes the 140-day cycle. Spending on assets: ₹143 Cr over the last 3 years, against ₹302 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹205 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Solara Active Pharma Sciences' P/E ratio, and how does it compare with its own history? Solara Active Pharma Sciences Ltd's P/E is 64.6×, in the middle of its own history: higher than 65% of past readings. Its usual P/E (the middle reading) is 33.2×, over 8.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹7.07. Why the multiple is where it is: over the past year earnings per share moved −1,466.7% while the price moved +5.0%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved −11.4% a year; about −27.3% a year came from earnings growth and about +15.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Solara Active Pharma Sciences business getting better or worse? Solara Active Pharma Sciences Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Solara Active Pharma Sciences earn on its capital? Solara Active Pharma Sciences Ltd earned a ROCE of 5% in FY26. That is up from a low of −9% in FY24. Its return on capital used (ROIC) is 5.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −0.5% net margin and 0.59× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −0.5% net margin × 0.59× asset turnover × 1.86× leverage (assets divided by equity) ≈ −0.5% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 6.8% − 12.0% = −5.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 6.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 4.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Solara Active Pharma Sciences have too much debt? Solara Active Pharma Sciences Ltd has total debt of ₹591 Cr against shareholder equity of ₹1,439 Cr as of Sep 2026, so its debt is 0.41× its equity. Year by year, that ratio went from 0.68 in FY22 to 0.55 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Solara Active Pharma Sciences shareholding pattern? Promoters raised their stake in Solara Active Pharma Sciences Ltd by 4.7 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 41.9% of the company. Foreign institutions moved −4.0 points over the same period, to 10.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +4.7 points over 8 quarters, to 41.9%; Foreign institutions: −4.0 points over 8 quarters, to 10.7%; Domestic institutions: +0.7 points over 8 quarters, to 3.9%. Why the owners changed: promoters drove it (+4.7 points), with the other side taken by foreign institutions (−4.0 points). They raised their stake step by step. ## How far is Solara Active Pharma Sciences from balance-sheet trouble? For Solara Active Pharma Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Solara Active Pharma Sciences rank in its industry? 49.5 out of 100, rank 13 of 24 in Pharma - API & CRAMS, with 74% of the evidence available. Solara Active Pharma Sciences Ltd scores 49.5 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 13. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.8 + 7.2 + 9.7 + 10.8 = 49.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Solara Active Pharma Sciences compared with? Solara Active Pharma Sciences ranks 13 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 49.5 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. Solara Active Pharma Sciences Ltd this page SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue 27.3% · Profit 100% · Operating margin change 7 points · 74% evidence Capital efficiency 7.2/25 · ROCE 4.9% · Operating margin 18% · 100% evidence Valuation 9.7/20 · P/E 64.9× · PEG n/a · 15% evidence Relative strength 10.8/20 · Lead over its industry -9.7% · Lead over NIFTY 500 19.2% · 1 year 5.5% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 7.2 + 9.7 + 10.8 = 49.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Solara Active Pharma Sciences in size? Solara Active Pharma Sciences is the 21st largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Morepen Laboratories, IOL Chemicals & Pharmaceuticals and SMS Pharmaceuticals. Just below it: Hikal, Dishman Carbogen Amcis and Windlas Biotech. ### Pharma - API & CRAMS companies close in size

1. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) ₹6,211 crore
2. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) ₹5,215 crore
3. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) ₹4,789 crore
4. Solara Active Pharma Sciences Ltd ₹3,070 crore
5. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) ₹2,609 crore
6. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) ₹2,274 crore
7. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) ₹1,808 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [TruAlt Bioenergy Ltd](https://www.sectoralpha.in/stocks/trualt-bioenergy-ltd) ₹3,084 crore · Miscellaneous
2. [Lords Mark Industries Limited](https://www.sectoralpha.in/stocks/lords-mark-industries-limited) ₹3,079 crore · Miscellaneous
3. Solara Active Pharma Sciences Ltd ₹3,070 crore
4. [J Kumar Infraprojects Ltd](https://www.sectoralpha.in/stocks/j-kumar-infraprojects-ltd) ₹3,069 crore · EPC
5. [Sangam (India) Ltd](https://www.sectoralpha.in/stocks/sangam-indialtd) ₹3,059 crore · Textiles - Spinning

## What else do people ask about Solara Active Pharma Sciences? ### What is Solara Active Pharma Sciences's share price today? Solara Active Pharma Sciences Ltd's share price is ₹629.75, +5.0% over the past year. The whole company is worth ₹3,054 Cr on the market. In the last 52 weeks it traded between ₹441 to ₹749; today it is 61% of the way up from the low, 6.6% above its 200-day average (as of 3 November 2026). ### What were Solara Active Pharma Sciences's latest quarterly results? Solara Active Pharma Sciences Ltd reported revenue of ₹417 Cr and net profit of ₹28.0 Cr for the Sep 2026 quarter. Earnings per share were ₹5.86. The operating margin was 18.0%, 7.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Solara Active Pharma Sciences's market cap? Solara Active Pharma Sciences Ltd's market capitalisation is ₹3,054 Cr at a share price of ₹629.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Solara Active Pharma Sciences performing? Solara Active Pharma Sciences Ltd's share price has been rising for 19 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 12 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Solara Active Pharma Sciences's share price go up? This page does not forecast Solara Active Pharma Sciences Ltd's share price. What it shows instead: the share price is ₹629.75, and it has been rising for 19 weeks. Its P/E of 64.6× is higher than 65% of its own last 8 years (as of 3 November 2026). ### Who owns Solara Active Pharma Sciences? Promoters own 41.9% of Solara Active Pharma Sciences Ltd, foreign institutions 10.7%, domestic institutions 3.9% and the public 43.5% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 4.7 percentage points over 8 quarters (as of 3 November 2026). ### Does Solara Active Pharma Sciences have too much debt? Solara Active Pharma Sciences Ltd has a moderate amount of debt: its debt is 0.55× its equity, and its operating profit is 2 times its interest bill. FY26 borrowings were ₹687 Cr against equity of ₹1,253 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Is Solara Active Pharma Sciences's profit real cash? Yes, over the last 3 years, 181% of Solara Active Pharma Sciences Ltd's reported profit came in as cash from operations. The latest year was lower at -2186%, so the trend is worth watching. In FY26, operating cash was ₹153 Cr against reported profit of −₹7.0 Cr. Most of that cash then goes into a mix of the daily operating cycle and new capacity. These are yearly figures (as of 3 November 2026). ### Where is Solara Active Pharma Sciences in its business cycle? Solara Active Pharma Sciences Ltd's FY26 operating margin was 14.0%, against a 9-year range of −7.0% to 24.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 18.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Solara Active Pharma Sciences story? The main question: the share price moved +5.0% in a year while yearly earnings per share moved −1,466.7%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Solara Active Pharma Sciences a stock worth studying right now? What the numbers show: Solara Active Pharma Sciences Ltd's share price has risen faster than its earnings: +5.0% in a year, against −1,466.7% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Solara Active Pharma Sciences share price forecast for 2026? What management itself guided: FY27 goal of five DMF submissions, with two completed and three more hoped for by year-end. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.